Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norgine b.v. - ascorbinsyre, kaliumchlorid, macrogol 3350, natriumascorbat, natriumchlorid, natriumsulfat, vandfrit - pulver til oral opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris aps - kaliumchlorid, macrogol 3350, natriumchlorid, natriumhydrogencarbonat - pulver til oral opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norgine b.v. - ascorbinsyre, kaliumchlorid, macrogol 3350, natriumascorbat, natriumchlorid, natriumsulfat, vandfrit - pulver til oral opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - kaliumchlorid, macrogol 3350, natriumchlorid, natriumhydrogencarbonat - pulver til oral opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

galen ltd. - kaliumchlorid, macrogol 3350, natriumchlorid, natriumhydrogencarbonat - pulver til oral opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norgine healthcare b.v. - kaliumchlorid, macrogol 3350, natriumchlorid, natriumhydrogencarbonat - pulver til oral opløsning, enkeltdosisbeholder

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tillotts pharma ab - kaliumchlorid, macrogol 3350, natriumchlorid, natriumhydrogencarbonat - pulver til oral opløsning

Den europeiske union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Den europeiske union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Den europeiske union - dansk - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazon - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i. triple kombinationsbehandling) som supplement til diæt og motion til forbedring af glykæmisk kontrol hos voksne patienter (specielt overvægtige patienter), der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og pioglitazone. desuden incresync kan bruges til at erstatte separate tabletter af alogliptin og pioglitazone i disse voksne patienter i alderen 18 år og ældre med type 2-diabetes mellitus, der allerede er i behandling med denne kombination. efter initiering af behandling med incresync, patienter bør revideres efter tre til seks måneder til at vurdere tilstrækkeligheden af respons på behandlingen (e. reduktion i hba1c). hos patienter, der undlader at vise et passende svar, incresync bør seponeres. i lyset af potentielle risici med langvarig pioglitazone terapi, ordinerende læger bør bekræftes ved en efterfølgende rutinemæssige vurderinger, der har gavn af incresync bevares (se afsnit 4.